Fusicoccin A, a phytotoxic carbotricyclic diterpene glucoside of fungal origin, reduces proliferation and invasion of glioblastoma cells by targeting multiple tyrosine kinases
Bury, M; Andolfi, A; Rogister, Bernardet al.
2013 • In Translational Oncology, 6(2), p. 112-123
Rogister, Bernard ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biochimie et physiologie générales, et biochimie humaine
Cimmino, A
Mégalizzi, V
Mathieu, V
Feron, O
Evidente, A
Kiss, R
Language :
English
Title :
Fusicoccin A, a phytotoxic carbotricyclic diterpene glucoside of fungal origin, reduces proliferation and invasion of glioblastoma cells by targeting multiple tyrosine kinases
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, and Kleihues P (2007). The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114, 97-109.
Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, et al. (2007). Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21, 2683-2710.
Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al. (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10, 459-466.
Louis DN (2006). Molecular pathology of malignant gliomas. Annu Rev Pathol 1, 97-117.
Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et al. (2008). An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807-1812.
Yung WK, Vredenburgh JJ, Cloughesy TF, Nghiemphu P, Klencke B, Gilbert MR, Reardon DA, and PradosMD (2010). Safety and efficacy of erlotinib in firstrelapse glioblastoma: a phase II open-label study. Neuro Oncol 12, 1061-1070.
De Fazio S, Russo E, Ammendola M, Donato Di Paola E, and De Sarro G (2012). Efficacy and safety of bevacizumab in glioblastomas. Curr Med Chem 19, 972-981.
Gilbert MR, Kuhn J, Lamborn KR, Lieberman F, Wen PY, Mehta M, Cloughesy T, Lassman AB, Deangelis LM, Chang S, et al. (2012). Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. J Neurooncol 106, 147-153.
Greve H, Mohamed IE, Pontius A, Kehraus S, Gross H, and Konig GM (2010). Fungal metabolites: structural diversity as incentive for anticancer drug development. Phytochem Rev 9, 537-545.
Newman DJ and Cragg GM (2012). Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 75, 311-335.
Fountzilas G, Karavelis A, Capizzello A, Kalogera-Fountzila A, Karkavelas G, Zamboglou N, Selviaridis P, Foroglou G, and Tourkantonis A (1999). Radiation and concomitant weekly administration of paclitaxel in patients with glioblastoma multiforme. A phase II study. J Neurooncol 45, 159-165.
Vredenburgh JJ, Desjardins A, Reardon DA, and Friedman HS (2009). Experience with irinotecan for the treatment of malignant glioma. Neuro Oncol 11, 80-91.
Fruehauf JP, Brem H, Brem S, Sloan A, Barger G, Huang W, and Parker R (2006). In vitro drug response and molecular markers associated with drug resistance in malignant gliomas. Clin Cancer Res 12, 4523-4532.
Ballio A, Chain EB, De Leo P, Erlanger BF, Mauri M, and Tonolo A (1964). Fusicoccin: a new wilting toxin produced by Fusicoccum amygdali. Nature 203, 297.
Mackintosh C (2004). Dynamic interactions between 14-3-3 proteins and phosphoproteins regulate diverse cellular processes. Biochem J 381, 329-342.
Bunney TD, De Boer AH, and Levin M (2003). Fusicoccin signaling reveals 14-3-3 protein function as a novel step in left-right patterning during amphibian embryogenesis. Development 130, 4847-4858.
Takahashi M, Kawamura A, Jato N, Nishi T, Hamachi I, and Ohkanda J (2012). Phosphopeptide-dependent labeling of 14-3-3ζ proteins by fusicoccinbased fluorescent probes. Angew Chem Int Ed Engl 51, 509-512.
Yang X, Cao W, Lin H, Zhang W, Lin W, Cao L, Zhen H, Huo J, and Zhang X (2009). Isoform-specific expression of 14-3-3 proteins in human astrocytoma. J Neurol Sci 276, 54-59.
de Vries-van Leeuwen IJ, Kortekaas-Thijssen C, Nzigou Mandouckou JA, Kas S, Evidente A, and de Boer AH (2010). Fusicoccin-A selectively induces apoptosis in tumor cells after interferon-α priming. Cancer Lett 293, 198-206.
Ballio A, Carilli A, Santurbano B, and Tuttobello L (1968). Produzione di fusicoccina in scala pilota. Ann Ist Super Sanita 4, 317-332.
Evidente A, Andolfi A, Fiore A, Boari A, and Vurro M (2006). Stimulation of Orobanche ramosa seed germination by fusicoccin derivatives: a structure-activity relationship study. Phytochemistry 67, 19-26.
Martinive P, De Wever J, Bouzin C, Baudelet C, Sonveaux P, Grégoire V, Gallez B, and Feron O (2006). Reversal of temporal and spatial heterogeneities in tumor perfusion identifies the tumor vascular tone as a tunable variable to improve drug delivery. Mol Cancer Ther 5, 1620-1627.
Lee S, Qiao J, Paul P, O'Connor KL, Evers BM, and Chung DH (2012). FAK is a critical regulator of neuroblastoma liver metastasis. Oncotarget.
Mosmann T (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65, 55-63.
Debeir O, Mégalizzi V, Warzée N, Kiss R, and Decaestecker C (2008). Videomicroscopic extraction of specific information on cell proliferation and migration in vitro. Exp Cell Res 314, 2985-2998.
Mégalizzi V, Decaestecker C, Debeir O, Spiegl-Kreinecker S, Berger W, Lefranc F, Kast RE, and Kiss R (2009). Screening of anti-glioma effects induced by sigma-1 receptor ligands: potential new use for old anti-psychiatric medicines. Eur J Cancer 45, 2893-2905.
Debeir O, Van Ham P, Kiss R, and Decaestecker C (2005). Tracking of migrating cells under phase-contrast video microscopy with combined mean-shift processes. IEEE Trans Med Imaging 24, 697-711.
Le Calvé B, Lallemand B, Perrone C, Lenglet G, Depauw S, Van Goietsenoven G, Bury M, Vurro M, Herphelin F, Andolfi A, et al. (2011). In vitro anticancer activity, toxicity and structure-activity relationships of phyllostictine A, a natural oxazatricycloalkenone produced by the fungus Phyllosticta cirsii. Toxicol Appl Pharmacol 254, 8-17.
Lallemand B, Chaix F, Bury M, Bruyère C, Ghostin J, Becker JP, Delporte C, Gelbcke M, Mathieu V, Dubois J, et al. (2011). N-(2-{3-[3,5-bis(trifluoromethyl) phenyl]ureido}ethyl)-glycyrrhetinamide (6b): a novel anticancer glycyrrhetinic acid derivative that targets the proteasome and displays anti-kinase activity. J Med Chem 54, 6501-6513.
Mégalizzi V, Mathieu V, Mijatovic T, Gailly P, Debeir O, De Neve N, Van Damme M, Bontempi G, Haibe-Kains B, Decaestecker C, et al. (2007). 4-IBP, a sigma1 receptor agonist, decreases the migration of human cancer cells, including glioblastoma cells, in vitro and sensitizes them in vitro and in vivo to cytotoxic insults of proapoptotic and proautophagic drugs. Neoplasia 9, 358-369.
Le Mercier M, Fortin S, Mathieu V, Roland I, Spiegl-Kreinecker S, Haibe-Kains B, Bontempi G, Decaestecker C, Berger W, Lefranc F, et al. (2009). Galectin 1 proangiogenic and promigratory effects in the Hs683 oligodendroglioma model are partly mediated through the control of BEX2 expression. Neoplasia 11, 485-496.
Lamoral-Theys D, Wauthoz N, Heffeter P, Mathieu V, Jungwirth U, Lefranc F, Nève J, Dubois J, Dufrasne F, Amighi K, et al. (2012). Trivanillic polyphenols with anticancer cytostatic effects through the targeting of multiple kinases and intracellular Ca2+ release. J Cell Mol Med 16, 1421-1434.
Gomez-Manzano C, Fueyo J, Kyritsis AP, McDonnell TJ, Steck PA, Levin VA, and Yung WK (1997). Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis. J Natl Cancer Inst 89, 1036-1044.
Dittmann LM, Danner A, Gronych J, Wolter M, Stühler K, Grzendowski M, Becker N, Bageritz J, Goidts V, Toedt G, et al. (2012). Downregulation of PRDX1 by promoter hypermethylation is frequent in 1p/19q-deleted oligodendroglial tumours and increases radio-and chemosensitivity of Hs683 glioma cells in vitro. Oncogene 31, 3409-3418.
Carragher NO and Frame MC (2004). Focal adhesion and actin dynamics: a place where kinases and proteases meet to promote invasion. Trends Cell Biol 14, 241-249.
Traxler P (2003). Tyrosine kinases as targets in cancer therapy-successes and failures. Expert Opin Ther Targets 7, 215-234.
McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG, and Frame MC (2005). The role of focal-adhesion kinase in cancer-a new therapeutic opportunity. Nat Rev Cancer 5, 505-515.
Zhao X and Guan JL (2003). Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. Adv Drug Deliv Rev 63, 610-615.
Parsons JT (2003). Focal adhesion kinase: the first ten years. J Cell Sci 116, 1409-1416.
Kim LC, Song L, and Haura EB (2009). Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 6, 587-595.
Xu LH, Owens LV, Sturge GC, Yang X, Liu ET, Craven RJ, and Cance WG (1996). Attenuation of the expression of the focal adhesion kinase induces apoptosis in tumor cells. Cell Growth Differ 7, 413-418.
Gabarra-Niecko V, Schaller MD, and Dunty JM (2003). FAK regulates biological processes important for the pathogenesis of cancer. Cancer Metastasis Rev 22, 359-374.
Skuli N, Monferran S, Delmas C, Favre G, Bonnet J, Toulas C, and Cohen-Jonathan Moyal E (2009). αvβ3/αvβ5 Integrins-FAK-RhoB: a novel pathway for hypoxia regulation in glioblastoma. Cancer Res 69, 3308-3316.
Natarajan M, Hecker TP, and Gladson CL (2003). FAK signaling in anaplastic astrocytoma and glioblastoma tumors. Cancer J 9, 126-133.
Reardon DA, Rich JN, Friedman HS, and Bigner DD (2006). Recent advances in the treatment of malignant astrocytoma. J Clin Oncol 24, 1253-1265.
Nakada M, Hayashi Y, and Hamada J (2011). Role of Eph/ephrin tyrosine kinase in malignant glioma. Neuro Oncol 13, 1163-1170.
Torsoni AS, Marin TM, Velloso LA, and Franchini KG (2005). RhoA/ROCK signaling is critical to FAK activation by cyclic stretch in cardiac myocytes. Am J Physiol Heart Circ Physiol 289, 1488-1496.
Lamalice L, Houle F, Jourdan G, and Huot J (2004). Phosphorylation of tyrosine 1214 on VEGFR2 is required for VEGF-induced activation of Cdc42 upstream of SAPK2/p38. Oncogene 23, 434-445.
Lowry WE, Huang J, Ma YC, Ali S, Wang D, Williams DM, Okada M, Cole PA, and Huang XY (2002). Csk, a critical link of g protein signals to actin cytoskeletal reorganization. Dev Cell 2, 733-744.
Angers-Loustau A, Hering R, Werbowetski TE, Kaplan DR, and Del Maestro RF (2004). SRC regulates actin dynamics and invasion of malignant glial cells in three dimensions. Mol Cancer Res 2, 595-605.
Wadhwa S, Nag TC, Jindal A, Kushwaha R, Mahapatra AK, and Sarkar C (2003). Expression of the neurotrophin receptors Trk A and Trk B in adult human astrocytoma and glioblastoma. J Biosci 28, 181-188.
Sjöström S, Wibom C, Andersson U, Brännström T, Broholm H, Johansen C, Collatz-Laier H, Liu Y, Bondy M, Henriksson R, et al. (2011). Genetic variations in VEGF and VEGFR2 and glioblastoma outcome. J Neurooncol 104, 523-527.
Lipinski CA, Tran NL, Menashi E, Rohl C, Kloss J, Bay RC, Berens ME, and Loftus JC (2005). The tyrosine kinase pyk2 promotes migration and invasion of glioma cells. Neoplasia 7, 435-445.
Siesser PM and Hanks SK (2006). The signaling and biological implications of FAK overexpression in cancer. Clin Cancer Res 12, 3233-3237.
Rong Y, Durden DL, Van Meir EG, and Brat DJ (2006). 'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol 65, 529-539.
Pistollato F, Abbadi S, Rampazzo E, Persano L, Della Puppa A, Frasson C, Sarto E, ScienzaR, D'avellaD, and BassoG(2010). Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma. Stem Cells 28, 851-862.
Bar EE (2011). Glioblastoma, cancer stem cells and hypoxia. Brain Pathol 21, 119-129.
Frosina G (2011). Frontiers in targeting glioma stem cells. Eur J Cancer 47, 496-507.
